245 Development and application of physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model for dose optimization of TAK-102: GPC3 targeted CAR-T armored with IL-7 and CCL-19

• Yasutoshi Kuboki,
• Takako Eguchi Nakajima,
• Takafumi Koyama,
• Eriko Sumi,
• Kotaro Suzuki,
• Agnish Dey,
• Hideaki Kagehara,
• Petar Pop-Damkov,
• Eiki Maeda,
• Takenori Akaike,
• Kondala Atkuri,
• Masashi Ochi,
• Ganesh M Mugundu,
• Aman Singh

Affiliations

Yasutoshi Kuboki

6National Cancer Center Hospital East, Kashiwa, Japan

Takako Eguchi Nakajima

7Kyoto University Graduate School of Medicine, Kyoto, Japan

Takafumi Koyama

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

Eriko Sumi

2Takeda Pharmaceutical Company Limited, Osaka, Japan

Kotaro Suzuki

3Takeda Pharmaceuticals, Cambridge, MA, USA

Agnish Dey

1Takeda Pharmaceuticals, Lexington, MA, USA

Hideaki Kagehara

2Takeda Pharmaceutical Company Limited, Osaka, Japan

Petar Pop-Damkov

3Takeda Pharmaceuticals, Cambridge, MA, USA

Eiki Maeda

4Takeda Pharmaceuticals, Fujisawa, Japan

Takenori Akaike

2Takeda Pharmaceutical Company Limited, Osaka, Japan

Kondala Atkuri

3Takeda Pharmaceuticals, Cambridge, MA, USA

Masashi Ochi

3Takeda Pharmaceuticals, Cambridge, MA, USA

Ganesh M Mugundu

3Takeda Pharmaceuticals, Cambridge, MA, USA

Aman Singh

3Takeda Pharmaceuticals, Cambridge, MA, USA